Novel 2,3-Dihydrobenzofuran-2-carboxylic Acids: Highly Potent and Subtype-Selective PPARα Agonists with Potent Hypolipidemic Activity
摘要:
The design and synthesis of a novel class of 2,3-dihydrobenzofuran-2-carboxylic acids as highly potent and subtype-selective PPAR alpha agonists are reported. Systematic study of structure-activity relationships has identified several key structural elements within this class for maintaining the potency and subtype selectivity. Select compounds were evaluated in animal models of dyslipidemia using Syrian hamsters and male Beagle dogs, and all these compounds displayed excellent cholesterol- and triglyceride-lowering activity at dose levels that were much lower than the marketed weak PPAR alpha agonist fenofibrate.
Novel 2,3-Dihydrobenzofuran-2-carboxylic Acids: Highly Potent and Subtype-Selective PPARα Agonists with Potent Hypolipidemic Activity
摘要:
The design and synthesis of a novel class of 2,3-dihydrobenzofuran-2-carboxylic acids as highly potent and subtype-selective PPAR alpha agonists are reported. Systematic study of structure-activity relationships has identified several key structural elements within this class for maintaining the potency and subtype selectivity. Select compounds were evaluated in animal models of dyslipidemia using Syrian hamsters and male Beagle dogs, and all these compounds displayed excellent cholesterol- and triglyceride-lowering activity at dose levels that were much lower than the marketed weak PPAR alpha agonist fenofibrate.
COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS
申请人:Epple Robert
公开号:US20100035944A1
公开(公告)日:2010-02-11
The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating G protein-coupled receptor 20 (GPR20), and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated GPR20.
[EN] COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR MODULER DES RÉCEPTEURS COUPLÉS AUX PROTÉINES G
申请人:IRM LLC
公开号:WO2008103501A1
公开(公告)日:2008-08-28
[EN] The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating G protein-coupled receptor 20 (GPR20), and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated GPR20. [FR] L'invention concerne des composés et leurs compositions pharmaceutiques, qui sont utiles pour moduler un récepteur 20 couplé aux protéines G (GPR20), et des procédés pour utiliser de tels composés pour traiter, améliorer ou prévenir une affection associée à un GPR20 anormal ou dérégulé.
Novel 2,3-Dihydrobenzofuran-2-carboxylic Acids: Highly Potent and Subtype-Selective PPARα Agonists with Potent Hypolipidemic Activity
作者:Guo Q. Shi、James F. Dropinski、Yong Zhang、Conrad Santini、Soumya P. Sahoo、Joel P. Berger、Karen L. MacNaul、Gaochao Zhou、Arun Agrawal、Raul Alvaro、Tian-quan Cai、Melba Hernandez、Samuel D. Wright、David E. Moller、James V. Heck、Peter T. Meinke
DOI:10.1021/jm050373g
日期:2005.8.1
The design and synthesis of a novel class of 2,3-dihydrobenzofuran-2-carboxylic acids as highly potent and subtype-selective PPAR alpha agonists are reported. Systematic study of structure-activity relationships has identified several key structural elements within this class for maintaining the potency and subtype selectivity. Select compounds were evaluated in animal models of dyslipidemia using Syrian hamsters and male Beagle dogs, and all these compounds displayed excellent cholesterol- and triglyceride-lowering activity at dose levels that were much lower than the marketed weak PPAR alpha agonist fenofibrate.